Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-09-20

FDA Approved: PERJETA — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for PERJETA (pertuzumab) filed by Genentech, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Perjeta (pertuzumab)

Snippet

SUPPL AP for PERJETA (PERTUZUMAB)